tirzepatide from lilly direct releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Lilly Direct 15mg vials :

40 weeks Headline result All tirzepatide doses superior

Most patients experience diarrhea for 14 weeks during initial titration

A peptide is a tool, not a full plan, so these drawbacks are easier to manage when peptide therapy is paired with an approach that addresses the root causes behind the weight

[DOI] [PubMed] [Google Scholar] 33.Madhusudhanan J, Suresh G, Devanathan V

Tirzepatide Regulatory Status in Canada Health Canada Approval Status (Mounjaro and Zepbound) Tirzepatide is the active ingredient in two Eli Lilly Canada products authorized by Health Canada: Mounjaro (authorized 2022 to improve glycemic control in adults with type 2 diabetes) and Zepbound (authorized May 13, 2025 for chronic weight management in adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity)